Sandoz Group AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1986-01-01

Employees: 20K

Market Cap: $19B

Website: http://www.sandoz.com

Clinical Trials

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Non-Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)
Drug: Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 24

Registration Number: NCT00881179

To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Allergies

Interventions: Drug: Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)
Drug: Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 40

Registration Number: NCT00881127

To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Pain

Interventions: Drug: Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
Drug: Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 26

Registration Number: NCT00881231

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cefprozil 500 mg Tablets (Sandoz GmbH)
Drug: Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 26

Registration Number: NCT00881426

To Demonstrate the Relative Bioavailability of Cefzil 500 mg Cefprozil Tablets Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cefprozil 500 mg Tablets (Sandoz, GmbH)
Drug: Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 35

Registration Number: NCT00881855

To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions

Phase 1

Completed

Conditions: Allergies

Interventions: Drug: Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)
Drug: Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 40

Registration Number: NCT00881634

To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)
Drug: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 24

Registration Number: NCT00881400

To Demonstrate the Relative Bioavailability of Clarithromycin 250 mg Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Clarithromycin 250 mg Tablets (Geneva, USA)
Drug: Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)

First Posted Date: 2009-04-15

Last Posted Date: 2017-03-28

Lead Sponsor: Sandoz

Target Recruit Count: 32

Registration Number: NCT00881738

Comparative Bioavailability Study of Azithromycin 200mg/5mL Suspension Following a 600mg Dose Under Fed Conditions

Phase 1

Completed

Conditions: Infections

Interventions: Drug: Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer
Drug: Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC

First Posted Date: 2009-04-06

Last Posted Date: 2017-03-29

Lead Sponsor: Sandoz

Target Recruit Count: 42

Registration Number: NCT00875966

Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)

Phase 3

Withdrawn

Conditions: Anemia
Chronic Renal Insufficiency

Interventions: Drug: HX575 solution for s.c. administration

First Posted Date: 2009-03-26

Last Posted Date: 2015-06-02

Lead Sponsor: Sandoz

Registration Number: NCT00869856

Locations: 🇧🇬
MHAT "Sveta Anna", Varna, Bulgaria
🇧🇬
MHAT "Dr. Tota Venkova", Gabrovo, Bulgaria
🇫🇷
Polyclinique de Bordeaux-Nord, Bordeaux, France

and more 15 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy